Trials begin of plaque-removing device:
This article was originally published in Clinica
The first procedures using a new catheter-based device for removing plaque loosened during stenting of heart bypass patients have begun in the US. The PercuSurge device, made by the Sunnyvale, California company of the same name, consists of an angioplasty guidewire with a low-pressure occlusion balloon at its tip. The device has the European CE mark and the FDA has granted an investigational device exemption for a multicentre, randomised study of the device, called SAFER (saphenous vein grafts angioplasty free of embolism randomised study).
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.